Effect of zoledronic acid on tartrate-resistant acid phosphatase isoform type 5b and other bone markers in lung cancer patients with bone metastases
Wenqing Zhang1, Guilherme Rabinowits2, Damian Laber3, Goetz H Kloecker11James Graham Brown Cancer Center, University of Louisville, Louisville, KY, 2Dana-Farber Cancer Institute, Boston, MA, 3Division of Hematology/Oncology, University of Oklahoma, Tulsa, OK, USABackground: Up to 44% of lung cancer...
Saved in:
Main Authors: | Zhang W (Author), Rabinowits G (Author), Laber DA (Author), Kloecker GH (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
by: Deyan N. Davidov
Published: (2013) -
Zoledronic acid in the management of metastatic bone disease
by: Thomas J Polascik, et al.
Published: (2008) -
Inhibition of tartrate-resistant acid phosphatase 5 can prevent cardiac fibrosis after myocardial infarction
by: Shujun Yang, et al.
Published: (2024) -
Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid
by: Aft R
Published: (2012) -
Zoledronic Acid Ameliorates the Bone Turnover Activity and Periprosthetic Bone Preservation in Cementless Total Hip Arthroplasty
by: Allen Herng Shouh Hsu, et al.
Published: (2022)